An expanded access record providing Tideglusib in Congenital Myotonic Dystrophy, sponsored by AMO Pharma Limited. Available. Per ClinicalTrials.gov, last updated 2025-08-13.
Sponsored by AMO Pharma Limited · Expanded access
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This treatment plan is limited to a single patient with Congenital Myotonic Dystrophy, who is ineligible or otherwise unable to participate in ongoing clinical trials.
127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →AMO Pharma Limited is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AMO Pharma Limited